GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Total Long-Term Assets

Labiana Health (XMAD:LAB) Total Long-Term Assets : €32.02 Mil (As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Labiana Health's Total Long-Term Assets for the quarter that ended in Dec. 2022 was €32.02 Mil.


Labiana Health Total Long-Term Assets Historical Data

The historical data trend for Labiana Health's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Total Long-Term Assets Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Total Long-Term Assets
36.67 38.96 32.02

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Total Long-Term Assets 36.67 38.96 35.75 32.02

Labiana Health Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Labiana Health Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Labiana Health's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.